Type 2 Diabetes Patients Taking ACTOS (Pioglitazone HCl) 22% Less Likely To Be Hospitalized For Heart Attack Than Those Taking Rosiglitazone

September 18th, 2007 | Category: Diabetes

An observational study based on a claims database of close to 30,000 patients published in Pharmacoepidemiology and Drug Safety showed that ACTOS (pioglitazone HCl) was associated with a 22 percent lower risk of hospitalization for acute myocardial

infarction (AMI), commonly known as heart attack, in patients with type 2 diabetes when compared to rosiglitazone. [click link for full article]

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Type 2 Diabetes Patients More Likely To Develop Congestive Heart Failure When Given Rosiglitazone Or Pioglitazone
  • ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk Of Ischemic Cardiovascular Disease In Patients With Type 2 Diabetes
  • ACTOS Is Associated With A 38 Percent Lower Risk Of Heart Attack, New Research Shows
  • Pioglitazone Lowers Risk Of Heart Attack, Stroke And Death But Raises Heart Failure Risk Among Diabetes Type 2 Patients
  • New input Showed ACTOS(R) (pioglitazone HCl) Prevented Progression Of Atherosclerotic Plaque Volume In Patients With Type 2 Diabetes

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.